peppersite
Peptideintranasal

Selank

Selank is a lab-made peptide of seven amino acids, based on tuftsin, a small immune-related molecule the body makes on its own. It has been studied mainly in Russian human trials of anxiety, and in animal work on nerve-cell growth signals.

Researched for
NeuroinflammationSleep

At a glance

Type
Peptide
Given by
intranasal
Evidence
Not yet audited here; the reference library calls it emerging
Reported amount
250 mcg per Peptide Dosing Protocols. All 4 sources

How much to draw

Full calculator →
Your draw
–units
Fill in the three numbers to see the draw.
Amount per dose

Opened on 250 mcg, the figure Peptide Dosing Protocols reports for Selank. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Selank or for anything else, and nothing below has been checked against the study it came from.

250-500 mcg intranasally daily (or 0.15% solution per protocol)
Frequency
once or twice daily10-14 day cycles · Repeat cycles per provider direction
Route
intranasal
Reported by
Commonly published practitioner dosing range - provider confirmation required.
300-600 mcg per dose intranasal; 200-400 mcg per dose subcutaneous
Frequency
2-3 times daily (intranasal); once daily (SC, 5 days per week)30 days on, 30 days off; approximately 6
Route
subcutaneous or intranasal or oral
Reported by
Peptide Protocol Wiki
Standard: 250-500 mcg per day · Low: 250 mcg · High: 500 mcg
Frequency
once daily for SubQ; 14-21 days for intranasal4 weeks for SubQ; 14-21 days for intranasal · 4 weeks on, 4 weeks off for SubQ; 1-3 weeks off for intranasal
Route
Subcutaneous injection (SubQ) or intranasal nasal spray
Reported by
Peptide Dosing Protocols
What it saysHalf-life: Half-life Selank ~2-10 min plasma; 12-24 hr functional duration Semax ~3-5 min plasma; 20-24. The standard research-use SubQ schedule is 4 weeks on at 250-500 mcg per day.
Referenced at 250-500 mcg (0.25-0.5 mg) per dose. Nasal spray cited as the most common route; onset within 30-60 minutes, peak benefit after several days of consistent use.
Frequency
Nasal 1-3x daily; injection once daily or as needed
Route
nasal or subcutaneous
Reported by
Peptide Therapy Reference Text
What it saysAug 2026), secondary reference; provider confirmation required.
Reconstitution, as reported
  • Compounded intranasal solution/spray · Compounded intranasal solution - no reconstitution required
  • 3 mL, 6 mL, or 10 mL per 30 mg vial
Not yet audited

We have not published an audit on Selank. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

Selank appears to calm anxiety while leaving thinking clear, rather than dulling it the way many anti-anxiety drugs do. Researchers link it to changes at GABA docking sites that resemble how benzodiazepines act, to shifts in serotonin, dopamine and norepinephrine handling, to raised BDNF in the hippocampus in animals, and to slower breakdown of enkephalins. As of June 2026 there is no registered Western Phase 1 to 3 development programme, and that lack of Western validation is described as the main limit on the evidence.

In technical termsModulation of neuropeptide and immune signaling.

Reported side effects

Reported by users: mild redness or irritation where it is injected, described as short-lived; mild stinging or dryness in the nose with the spray; and mild headache, usually in the first few days.

Seen in studies: compared head-to-head with benzodiazepines in Russian trials, Selank produced similar anxiety relief without sedation, dependence, memory problems, tolerance or withdrawal.

Not ruled out: the FDA has flagged a theoretical risk of an unwanted immune reaction to compounded Selank, based on limited regulated safety data rather than a documented clinical signal. Effects alongside prescription anxiolytics, antidepressants and sedatives have not been formally studied, most published evidence covers short courses, and purity depends on supplier testing.

Who should avoid it

People who are pregnant, breastfeeding or trying to conceive: there is no human safety data for these groups.

People with an unmanaged psychiatric condition: sources say this needs supervised, FDA-approved care instead.

People with an active or recent allergic reaction to peptide products: listed as a reason to avoid it.

People already taking prescription anxiolytics, antidepressants or sedatives without clinician oversight: combination effects have not been formally studied.

People with an immune system disorder: sources say it should not be modulated without medical supervision.

Common questions

What is Selank?

Selank is a peptide developed in Russia and studied for easing anxiety, with mild focus support reported alongside. It is a synthetic analog of tuftsin, an immune-related molecule the body makes.

What amounts of Selank are reported in research?

Reported amounts and schedules for Selank differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

What is Selank's half-life?

Selank's plasma half-life is short, roughly 2 to 10 minutes. One Russian trial nonetheless reported anxiolytic carryover for about a week after the last dose.

How is Selank reconstituted?

That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.

Is Selank a nasal spray?

Yes. In Russia, Selank is sold as a prescription nasal spray for anxiety disorders.

Is Selank FDA-approved?

No. As of June 2026, Selank is not FDA-approved in the United States.

What are the most common Selank side effects?

The most commonly reported are mild irritation at the injection site, mild nasal stinging or dryness with the spray, and occasional mild headache. These come largely from Russian trials of short courses.

How does Selank compare to Semax?

Sources describe Selank as anxiety-first and Semax as focus-first.

Sources

  1. 01Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova (2008)
  2. 02Seredenin SB, et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova (2014)
  3. 03Seredenin SB, et al. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova (2015)
  4. 04Uchakina ON, Uchakin PN, Miasoedov NF, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Bulletin of Experimental Biology and Medicine (2008)
  5. 05Volkova A, Bondarenko E, Wei H, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology (2016)
  6. 06Filatova E, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in Pharmacology (2017)
  7. 07Kasian A, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. BioMed Research International (2017)
  8. 08Bakhmet AA, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Bulletin of Experimental Biology and Medicine (2020)
  9. 09Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady Biological Sciences (2008)
  10. 10Kost NV, Sokolov OI, Gabaeva MV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorganicheskaia Khimiia (2001)
  11. 11Kolik LG, et al. Selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating of BDNF content in the hippocampus and prefrontal cortex in rats. Bulletin of Experimental Biology and Medicine (2019)
  12. 12Wikipedia contributors Selank. Wikipedia (2026)

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things
CJC-1295

CJC-1295 No DAC, also called Modified GRF 1-29, is a short-acting lab-made copy of growth-hormone-releasing hormone (GHRH), the body's signal to release growth hormone. Published human studies cover the parent CJC-1295 compound, and no large trial has tested the No DAC version.

CJC-1295 / Ipamorelin (GH Pulse)

GH Pulse is a combination sold as one vial: CJC-1295, a copy of growth hormone-releasing hormone, together with Ipamorelin, a selective growth hormone secretagogue. It is studied for growth-hormone-axis support, recovery and body composition.

DSIP

DSIP, or delta sleep-inducing peptide, is a small natural peptide of nine amino acids, first isolated in the 1970s from the blood of sleeping rabbits. It has been studied mostly in animals and in a handful of small human sleep trials.

Epitalon

Epitalon, also spelled epithalon, is a lab-made peptide of four amino acids (Ala-Glu-Asp-Gly), also called AEDG. It is studied mainly for aging, in cells, in animals and in older non-blinded human work on the related pineal extract.

Ipamorelin

Ipamorelin, also called NNC 26-0161, is a lab-made peptide that prompts the pituitary gland to release a short pulse of the body's own growth hormone. It has been tested in healthy volunteers and in a trial of slow gut recovery after bowel surgery, where it did not show benefit.

Semax

Semax is a lab-made peptide of seven amino acids, built from a piece of the stress hormone ACTH with a short tail added to slow its breakdown. It is studied mainly as a nasal spray in rats and in Russian clinical work on stroke recovery, stress and cognition.